You are here

Phase 2 Trial of KOS-862 in Non-Small Cell Lung Cancer Halted

HAYWARD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences (NASDAQ:KOSN) today announced that its Phase II clinical trial of KOS-862 in non-small cell lung cancer (NSCLC) has been discontinued, while Phase II clinical trials in both breast and prostate cancers continue to advance. The KOS-862 trial in non-small cell lung cancer was terminated as the trial did not meet the primary objective of tumor response in the first step of the two-stage Simon trial design. The breast cancer trial initiated in February 2004 continues to enroll patients and is expected to generate sufficient data for an interim analysis in the first half of 2005; the prostate trial is expected to commence at multiple sites this calendar quarter.

"Although we have concluded the non-small cell lung cancer trial, the response rate of patients with prostate and breast cancers towards other epothilones leads us to be optimistic about the potential efficacy of KOS-862 in these types of tumors," said Daniel V. Santi, M.D., Ph.D., Chairman and Chief Executive Officer of Kosan.

William M. Burns, Head of Roche's Pharmaceuticals Division, added, "We are learning about this class of drugs and Roche will continue to work with Kosan on the development of KOS-862 for other indications, as well as advancing next-generation epothilone analogs through the pipeline."

Roche and Kosan entered into a global alliance for the co-development and commercialization of KOS-862 and its back up compounds in September 2002.

Source: Kosan Biosciences

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds